Effect of Empagliflozin on Circulating Proteomics in Heart Failure: Mechanistic Insights from the EMPEROR Program.
Faiez ZannadJoão Pedro FerreiraJaved ButlerGerasimos FilippatosJames L JanuzziMikhail SuminMatthias ZwickMaral SaadatiStuart J PocockNaveed SattarStefan D AnkerMilton PackerPublished in: European heart journal (2022)
Changes in circulating protein levels in patients with heart failure are consistent with the findings of experimental studies that have shown that the effects of SGLT2 inhibitors are likely related to actions on the heart and kidney to promote autophagic flux, nutrient deprivation signaling and transmembrane sodium transport.